Mystic Trial Results In Second Half of 2018



AstraZeneca on Monday said it expects to deliver final analysis of its phase III MYSTIC trial of Imfinzi in the second half of 2018 rather than the first half of the year as was previously anticipated. The MYSTIC trial is a randomised, open-label, multi-centre, global Phase III trial of Imfinzi monotherapy or Imfinzi in combination with tremelimumab versus SoC in treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally-advanced or metastatic (Stage IV) 1st-line NSCLC. Imfinzi is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Story provided by StockMarketWire.